Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...